AKT1 and Miyoshi myopathy: From our analysis, we noted that the combination of ponatinib and sirolimus in MM cells provides blocks on AKT and mTORC1 (downstream of various growth signals of tyrosine kinases), effectively blocking glycolysis and OXPHOS (both sources of ATP), and also generates ROS levels that prove to be catastrophic for these cells (Figure 8B).